Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Source: Senate LDA
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Drug Shortage Prevention Act of 2012
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
To suspend temporarily the duty on 3-[8-Amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin- 3-yl]-1-methyl-cyclobutanol (OSI-906).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP2408.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASP0777.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on 3-(1-Bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone (OSIP-690631, bicyclic intermediate).
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
To suspend temporarily the duty on placebos to be used in clinical trials for the drug ASKP1240.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Generating Antibiotic Incentives Now Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Preserving Access to Life-Saving Medications Act of 2011
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Cancer Care Improvement Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Data Accountability and Trust Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Data Accountability bill (HR 2221)
Data Accountability and Trust Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Data Accountability bill (HR 2221)
Cancer Drug Coverage Parity Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Cancer Drug Coverage Parity Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Strategies to Address Antimicrobial Resistance Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
American Medical Isotopes Production Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
To amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Generating Antibiotic Incentives Now Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Generating Antibiotic Incentives Now Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Medicare Home Infusion Therapy Coverage Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
A bill to suspend temporarily the suspension of duty on RSD 1235.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Prostate Research, Outreach, Screening, Testing, Access, and Treatment Effectiveness Act of 2010
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
American Middle Class Tax (AMT) Relief Act of 2007
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · 3A
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · first_quarter · Q1
Issues related to the pharmaceutical sales fee (no specific bills) Issues related to the renewal of the R&D tax credit (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (no specific bills) Issues related to the supply of medical isotopes (the American Medical Isotopes Production Act (S.99)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · fourth_quarter · Q4
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753/HR 6517)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · third_quarter · Q3
Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).
The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · second_quarter · 2A
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · first_quarter · 1A
Issues related to Data Accountability bill (HR 2221)
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · second_quarter · Q2
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2010 · first_quarter · Q1
Tariff duty suspension for RSD 1235, (a bill to extend temporarily the suspension of duty on RSD 1235, (S 2753))
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy CoverageAct of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2009 · fourth_quarter · Q4
Issues pertaining to antimicrobial resistance (HR 2400); Issues pertaining to community and healthcare associated infections; Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)); Issues related to 340B program, drug importation and follow-on biologics (America's Affordable Health Choices Act of 2009 (HR 3200); Service Member's Home Ownership Tax Act of 2009 (HR 3590); America's Healthy Future Act of 2009 (S 1796); (continued next page) (continued from previous page) - Affordable Health Choices Act (S. 1679); Affordable Health Care for America Act (HR 3962)).
Tariff duty suspension
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2009 · third_quarter · Q3
Issues pertaining to antimicrobial resistance (HR 2400); issues pertaining to community and healthcare associated infections; issues pertaining to medical isotopes (HR 3276); issues related to 340B program; The Affordable Health Choices Act (S. 1679)
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S254): The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565); Issues related to Medicare Hospital Outpatient Prospective Payment System; America's Affordable Health Choices Act (HR 3200): America's Healthy Future Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2009 · second_quarter · Q2
Issues pertaining to antimicrobial resistance (HR 2400); Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to ensuring access to critical medications under Medicare Part D; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S 254); The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565).
Tariff duty suspension
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2009 · first_quarter · Q1
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to ensuring access to critical medications under Medicare Part D; The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act.
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · fourth_quarter · Q4
S. 3560, QI Program Supplemental Funding Act of 2008, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions.
S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S. Res. 454 and H. Res. 988, designating March 2008 as MRSA Awareness Month; Issues related to antibiotics and infectious dissease control.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · third_quarter · Q3
H.R. 6432, Animal Drug User Fee Amendments Act of 2008; S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S. 3560, QI Program Supplemental Funding Act of 2008; S. Res. 454 and H. Res. 988, designating March 2008 as MRSA Awareness Month; Issues related to antibiotics and infectious dissease control.
H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · second_quarter · Q2
S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, the Community and Healthcare Associated Infections (CHAI) Reduction Act; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month; Issues related to Hatch-Waxman
S. 3101 and H.R. 6331, the Medicare Improvements for Patients and Providers Act of 2008 and S. 3118, the Preserving Access to Medicare Act of 2008; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Issues related to implementation of Section 5001 (c) of the Deficit Reduction Act of 2005; Issues related to Medicare coverage of immunosuppressants; Issues related to Medicare Part Ds six classes of clinical concern; Issues related to Medicaid payment for hospital-acquired conditions; and issues related to Medicaid prior authorization
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · first_quarter · Q1
S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, Section 2(b), Prior Authorization Programs; S. 1887, the Medicare Access to Critical Medications Act of 2007; H.R. 3061, the Medicare Part D Drug Class Protection Act of 2007; Implementation of Section 5001 (c) of the 2005 Deficit Reduction Act; HR 3282 & S 2320, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007; Medicare payment for imaging.
Infectious disease issues, including S. 2313 and H.R. 3697 (the STAAR Act), S. 2278 (Community and Healthcare Associated Infections Reduction Act); prescription drug importation legislation; follow-on biologics legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · first_quarter · RR
S. 2313 and H.R. 3697, the STAAR Act; S. 2278, Community and Healthcare Associated Infections Reduction Act; Issues relating to the implementation of Section 5001 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, Section 2(b), Prior Authorization Programs; S. 1887, the Medicare Access to Critical Medications Act of 2007; H.R. 3061, the Medicare Part D Drug Class Protection Act of 2007
S. 2313 and H.R. 3697, the STAAR Act; S. 2278, Community and Healthcare Associated Infections Reduction Act; Issues relating to the implementation of Section 5001 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, Section 2(b), Prior Authorization Programs; S. 1887, the Medicare Access to Critical Medications Act of 2007; H.R. 3061, the Medicare Part D Drug Class Protection Act of 2007
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).
Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to antimicrobial resistance (Strategies to Address Antimicrobial Resistance Act, (HR 2400)) Issues pertaining to community and healthcare associated infections Issues pertaining to medical isotopes (American Medical Isotopes Production Act of 2009 (HR 3276)) Issues related to the study of clinical effectiveness for immunosuppressant drugs Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage, the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), the Health Care and Education Reconciliation Act of 2010 (HR4872). Issues related to comparative clinical effectiveness of immunosuppressant drugs. Issues related to oncology coverage, the 21st Century Cancer ALERT ("Access to Life-Saving Early detection, Research and Treatment" Act (HR1844)). Issues related to comparative clinical effectiveness
Issues related to Data Accountability bill (HR 2221)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
The Data Accountability and Trust Act (HR 2221)
Issues related to the implementation of Section 501(c) of the 2005 Deficit Reduction Act; Issues related to hospital readmissions/bundling and home infusion therapy coverage (HR 574/S 254); The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565); Issues related to Medicare Hospital Outpatient Prospective Payment System (HR 4371); Issues related to Medicare Part D dual eligibles rebate (see applicable bills on next page) (continued from previous page) - (America's Affordable Health Choices Act of 2009 (HR 3200); Service Member's Home Owenership Tax Act of 2009 (HR 3590); America's Healthy Future Act of 2009 (S 1796); Affordable Health Choices Act (S 1679); Affordable Health Care for America Act (HR 3962))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE